Advertisement
Dr. Nathan Lawrence, Vice President of Marketing for PBI, said: "TheFT500-ND is based on the field-proven FT500 PULSE Tube, the current, primaryconsumable of the PCT Sample Preparation System. The FT500-ND is similar tothe FT500 in look and feel, except there is no lysis disk in this new PULSETube. This design change was based on strong market demand for a new PCTconsumable for the rapid and reproducible processing of solutions andsuspensions that do not require partial homogenization by passage through alysis disk, and for a consumable that could accept smaller sample volumes. Itis the result of more than a year of testing in several laboratories usingvarious sample sizes and types. We are encouraged with the data generated todate, and believe that the new FT500-ND PULSE Tube and the three new PCT-dependent applications fill a large, growing, yet unmet need for a single-usePCT consumable that offers variable sample volumes (5x the range of theexisting FT500) and lacks a lysis disk. We believe that this importantaddition to our PCT product line should enable us to introduce PCT to a newgroup of research scientists, and that it should subsequently help drive ourfuture installed base of Barocycler instruments."
Advertisement
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused onthe development of a novel, enabling technology called Pressure CyclingTechnology (PCT). PCT uses cycles of hydrostatic pressure between ambient andultra-high levels (up to 35,000 psi and greater) to control bio-molecularinteractions. PBI currently holds 13 US and 6 foreign patents coveringmultiple applications of PCT in the life sciences field, including such areasas genomic and proteomic sample preparation, pathogen inactivation, thecontrol of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company'sintentions, hopes, beliefs, expectations, or predictions of the future are"forward-looking'' statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. These statements include the reportedeffectiveness of the new FT500-ND to extract biomolecules from bacteria andfungi in soil and skin cells, and mitochondria from cells; the variable samplevolumes allowed by the FT500-ND; the implication that the Company will developadditional applications for the FT500-ND; the perceived demand for the FT500-ND PULSE Tube and the three new PCT dependent applications; and the Company'sbelief that the introduction of the FT500-ND and the new PCT-dependentapplications will help to drive the installed base of PCT instruments. Thesestatements are based upon the Company's current expectations, forecasts, andassumptions that are subject to risks, uncertainties, and other factors thatcould cause actual outcomes and
